Investors emphasise the need for companies to increase voluntary licensing of medicines, after new benchmark report reveals slowdown. The Access to Medicine (ATM) Foundation and its investor signatories have urged pharmaceutical companies to improve access to medicines in low- and middle-income countries (LMICs) by accelerating voluntary licence agreements. Voluntary licences are private contractual agreements through which pharmaceutical firms holding patents…

Investors emphasise the need for companies to increase voluntary licensing of medicines, after new benchmark report reveals slowdown. The Access to Medicine (ATM) Foundation and its investor signatories have urged pharmaceutical companies to improve access to medicines in low- and middle-income countries (LMICs) by accelerating voluntary licence agreements. Voluntary licences are private contractual agreements through which pharmaceutical firms holding patents…

Investors emphasise the need for companies to increase voluntary licensing of medicines, after new benchmark report reveals slowdown. The Access to Medicine (ATM) Foundation and its investor signatories have urged pharmaceutical companies to improve access to medicines in low- and middle-income countries (LMICs) by accelerating voluntary licence agreements. Voluntary licences are private contractual agreements through which pharmaceutical firms holding patents…

Investors emphasise the need for companies to increase voluntary licensing of medicines, after new benchmark report reveals slowdown. The Access to Medicine (ATM) Foundation and its investor signatories have urged pharmaceutical companies to improve access to medicines in low- and middle-income countries (LMICs) by accelerating voluntary licence agreements. Voluntary licences are private contractual agreements through which pharmaceutical firms holding patents…

Investors emphasise the need for companies to increase voluntary licensing of medicines, after new benchmark report reveals slowdown. The Access to Medicine (ATM) Foundation and its investor signatories have urged pharmaceutical companies to improve access to medicines in low- and middle-income countries (LMICs) by accelerating voluntary licence agreements. Voluntary licences are private contractual agreements through which pharmaceutical firms holding patents…

Investors emphasise the need for companies to increase voluntary licensing of medicines, after new benchmark report reveals slowdown. The Access to Medicine (ATM) Foundation and its investor signatories have urged pharmaceutical companies to improve access to medicines in low- and middle-income countries (LMICs) by accelerating voluntary licence agreements. Voluntary licences are private contractual agreements through which pharmaceutical firms holding patents…

Investors emphasise the need for companies to increase voluntary licensing of medicines, after new benchmark report reveals slowdown. The Access to Medicine (ATM) Foundation and its investor signatories have urged pharmaceutical companies to improve access to medicines in low- and middle-income countries (LMICs) by accelerating voluntary licence agreements. Voluntary licences are private contractual agreements through which pharmaceutical firms holding patents…

Investors emphasise the need for companies to increase voluntary licensing of medicines, after new benchmark report reveals slowdown. The Access to Medicine (ATM) Foundation and its investor signatories have urged pharmaceutical companies to improve access to medicines in low- and middle-income countries (LMICs) by accelerating voluntary licence agreements. Voluntary licences are private contractual agreements through which pharmaceutical firms holding patents…

Investors emphasise the need for companies to increase voluntary licensing of medicines, after new benchmark report reveals slowdown. The Access to Medicine (ATM) Foundation and its investor signatories have urged pharmaceutical companies to improve access to medicines in low- and middle-income countries (LMICs) by accelerating voluntary licence agreements. Voluntary licences are private contractual agreements through which pharmaceutical firms holding patents…

Investors emphasise the need for companies to increase voluntary licensing of medicines, after new benchmark report reveals slowdown. The Access to Medicine (ATM) Foundation and its investor signatories have urged pharmaceutical companies to improve access to medicines in low- and middle-income countries (LMICs) by accelerating voluntary licence agreements. Voluntary licences are private contractual agreements through which pharmaceutical firms holding patents…